



**PRESS RELEASE**

02 September 2024 15:17:00 CEST

## **AcouSort to attend ISCT Europe to expand its network in the cell therapy space**

**On September 4-6, AcouSort will attend ISCT Europe in Gothenburg, Sweden, a conference that gathers an extensive network of cell and gene therapy professionals to address current topics and challenges to drive the field forward and break down barriers to enable greater access to patients.**

ISCT Europe offers a great opportunity for AcouSort to connect with global scientists, experts and potential customers, making it an ideal platform for the company to continue developing its network in the field of cell therapy.

We also present a poster at ISCT Europe together with the Karolinska Institute in Stockholm. The poster is number 43 at the conference and is entitled: *Enhancing cell therapy accessibility through bedside formulation: Employing an acoustic-based, automated cell trapping system for washing hPSC-derived RPE cells.*

“Attending the ISCT Europe is an important part of our ambition to expand our presence in the very dynamic cell therapy space. We already have a number of collaborations in this field, and we are looking forward to demonstrating how our acoustofluidic technology can be used to improve vital parts in cell therapy production,” says Agnes Michanek, Commercial Director at AcouSort.

**FOR FURTHER INFORMATION ABOUT ACOUSORT, PLEASE CONTACT:**

Torsten Freltoft, CEO

Telephone: +45 2045 0854

E-mail: [torsten.freltoft@acousort.com](mailto:torsten.freltoft@acousort.com)

**ABOUT ACOUSORT**

*AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify, and stain cells, exosomes, and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of-Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases, and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company's Certified Adviser is Carnegie Investment Bank AB (publ).*